{"answer":"\"<|im_start|> system\\n        Describe this for a person interested in life extension who is well educated about life extension methods.<|im_end|> \\n        <|im_start|> user\\n        1. Mol Inform. 2020 Jul;39(7):e1900165. doi: 10.1002/minf.201900165. Epub 2020\\nMar  10.\\n\\nDeciphering Imidazoline Off-targets by Fishing in the Class A of GPCR field.\\n\\nDjikic T(1), Vucicevic J(1), Laurila J(2), Radi M(3), Veljkovic N(4), Xhaard \\nH(5), Nikolic K(1).\\n\\nAuthor information:\\n(1)Department of Pharmaceutical Chemistry, Faculty of PharmacyUniversity of \\nBelgrade, Vojvode Stepe 450, 11000, Belgrade, Serbia.\\n(2)Research Center for Integrative Physiology and Pharmacology, Institute of \\nBiomedicine, University of Turku, FI-20014, Turun yliopisto, Turku, Finland.\\n(3)Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi \\ndi Parma, Viale delle Scienze, 27/A, 43124, Parma, Italy.\\n(4)Laboratory for bioinformatics and computational chemistry, Institute of \\nNuclear Sciences Vinca, University of Belgrade, Mihaila Petrovica Alasa 14, \\n11001, Belgrade, Serbia.\\n(5)Division of Pharmaceutical Chemistry, Drug Research Program, Division of \\nPharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of \\nHelsinki, P.O. Box 56, FI-00014, Helsinki, Finland.\\n\\nBased on the finding that a central antihypertensive agent with high affinity \\nfor I1-type imidazoline receptors - rilmenidine, shows cytotoxic effects on \\ncultured cancer cell lines, it has been suggested that imidazoline receptors \\nagonists might have a therapeutic potential in the cancer therapy. Nevertheless, \\npotential rilmenidine side effects caused by activation of α-adrenoceptors, or \\nother associated receptors and enzymes, might hinder its therapeutic benefits. \\nConsidering that human α-adrenoceptors belong to the rhodopsin-like class A of \\nG-protein-coupled receptors (GPCRs) it is reasonable to assume that imidazolines \\nmight have the affinity for other receptors from the same class. Therefore, to \\ninvestigate possible off-target effects of imidazoline ligands we have prepared \\na reverse docking protocol on class A GPCRs, using imidazoline ligands and their \\ndecoys. To verify our in silico results, three ligands with high scores and \\nthree ligands with low scores were tested for antagonistic activity on α2 - \\nadrenoceptors.\\n\\n© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.\\n\\nDOI: 10.1002/minf.201900165\\nPMID: 32078760 [Indexed for MEDLINE]\\n<|im_end|> \\n        <|im_start|> assistant\\n        Thank you for sharing the abstract of the article \\\"Deciphering Imidazoline Off-targets by Fishing in the Class A of GPCR field\\\" published in Mol Inform. 2020 Jul;39(7):e1900165. The article discusses research on the off-target effects of imidazoline ligands, which are compounds that bind to imidazoline receptors. These receptors are known to be involved in various physiological processes, including blood pressure regulation and possibly cancer therapy.\\n\\nThe study aimed to investigate whether imidazoline ligands could interact with other members of the rhodopsin-like class A of G-protein-coupled receptors (GPCRs) beyond their known targets. GPCRs are a large family of receptors that play crucial roles in cellular signaling, making them important drug targets.\\n\\nTo explore these potential off-targets, the authors used a computational approach called reverse docking, where they screened a set of imidazoline ligands and their decoys against class A GPCRs. Decoys are molecules designed to have similar properties to the ligands but without the desired biological activity. By comparing the interactions of the real ligands with those of the decoys, the researchers can identify potential binding sites and predict the likelihood of off-target interactions.\\n\\nThe results of this computational screen were then experimentally validated by testing the activity of selected ligands on α2-adrenoceptors, another member of the class A GPCRs. This step was likely taken to confirm if the predicted interactions had any functional consequences.\\n\\nFor someone interested in life extension and well-educated about life extension methods, this article provides insights into how computational methods can be used to uncover potential side effects and off-target interactions of pharmacological agents. Understanding these interactions is critical for developing safe and effective therapies, especially for conditions like cancer, where targeted treatments are essential to minimize damage to healthy tissues.\\n\\nIn summary, the article contributes to the growing body of knowledge on the complexity of GPCR interactions and how computational tools can help map out these intricate relationships, ultimately leading to more informed decisions in drug discovery and development.<|im_end|>\""}
----------------------------------------
{"answer":"\"<|im_start|> system\\n        Describe this for a person interested in life extension who is well educated about life extension methods.<|im_end|> \\n        <|im_start|> user\\n        1. Pharmacol Rev. 2020 Jan;72(1):50-79. doi: 10.1124/pr.118.016311.\\n\\nImidazoline Receptor System: The Past, the Present, and the Future.\\n\\nBousquet P(1), Hudson A(1), García-Sevilla JA(1), Li JX(2).\\n\\nAuthor information:\\n(1)Faculty of Medicine, University of Strasbourg, Strasbourg, France (P.B.); \\nDepartment of Pharmacology, University of Alberta, Edmonton, Alberta, Canada \\n(A.H.); Laboratory of Neuropharmacology, University Research Institute on Health \\nSciences, University of the Balearic Islands, Palma de Malllorca, Spain \\n(J.A.G.-S.); and Department of Pharmacology and Toxicology, University at \\nBuffalo, Buffalo, New York (J.-X.L.).\\n(2)Faculty of Medicine, University of Strasbourg, Strasbourg, France (P.B.); \\nDepartment of Pharmacology, University of Alberta, Edmonton, Alberta, Canada \\n(A.H.); Laboratory of Neuropharmacology, University Research Institute on Health \\nSciences, University of the Balearic Islands, Palma de Malllorca, Spain \\n(J.A.G.-S.); and Department of Pharmacology and Toxicology, University at \\nBuffalo, Buffalo, New York (J.-X.L.) junxuli@buffalo.edu.\\n\\nImidazoline receptors historically referred to a family of nonadrenergic binding \\nsites that recognize compounds with an imidazoline moiety, although this has \\nproven to be an oversimplification. For example, none of the proposed endogenous \\nligands for imidazoline receptors contain an imidazoline moiety but they are \\ndiverse in their chemical structure. Three receptor subtypes (I1, I2, and I3) \\nhave been proposed and the understanding of each has seen differing progress \\nover the decades. I1 receptors partially mediate the central hypotensive effects \\nof clonidine-like drugs. Moxonidine and rilmenidine have better therapeutic \\nprofiles (fewer side effects) than clonidine as antihypertensive drugs, thought \\nto be due to their higher I1/α 2-adrenoceptor selectivity. Newer I1 receptor \\nagonists such as LNP599 \\n[3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine \\nhydrochloride] have little to no activity on α 2-adrenoceptors and demonstrate \\npromising therapeutic potential for hypertension and metabolic syndrome. I2 \\nreceptors associate with several distinct proteins, but the identities of these \\nproteins remain elusive. I2 receptor agonists have demonstrated various \\ncentrally mediated effects including antinociception and neuroprotection. A new \\nI2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], \\ndemonstrated clear analgesic activity in a recently completed phase II clinical \\ntrial and holds great promise as a novel I2 receptor-based first-in-class \\nnonopioid analgesic. The understanding of I3 receptors is relatively limited. \\nExisting data suggest that I3 receptors may represent a binding site at the \\nKir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be \\ninvolved in insulin secretion. Despite the elusive nature of their molecular \\nidentities, recent progress on drug discovery targeting imidazoline receptors \\n(I1 and I2) demonstrates the exciting potential of these compounds to elicit \\nneuroprotection and to treat various disorders such as hypertension, metabolic \\nsyndrome, and chronic pain.\\n\\nCopyright © 2019 by The American Society for Pharmacology and Experimental \\nTherapeutics.\\n\\nDOI: 10.1124/pr.118.016311\\nPMID: 31819014 [Indexed for MEDLINE]\\n<|im_end|> \\n        <|im_start|> assistant\\n        For someone interested in life extension who is well-educated about life extension methods, the article you've provided offers insights into potential avenues for developing treatments that could improve healthspan and potentially extend lifespan. The focus on imidazoline receptors and the development of receptor agonists like LNP599 and CR4056 suggests that there may be opportunities to target specific pathways to address age-related diseases and conditions.\\n\\nHere's a breakdown of the key points from the abstract:\\n\\n1. **Historical Background**: The imidazoline receptor system was originally associated with a family of nonadrenergic binding sites recognizing compounds with an imidazoline group. However, it is now known that not all endogenous ligands for these receptors contain this moiety, indicating a more complex picture.\\n\\n2. **I1 Receptors and Hypertension**: I1 receptors play a role in the hypotensive effects of clonidine-like drugs. Newer I1 receptor agonists, such as LNP599, show promise for treating hypertension with fewer side effects compared to traditional drugs like clonidine.\\n\\n3. **I2 Receptors and Pain Management**: I2 receptors are associated with multiple proteins and have shown centrally mediated effects, including antinociception (pain relief) and neuroprotection. CR4056, an I2 receptor agonist, displayed promising analgesic properties in a phase II clinical trial, suggesting it might be a novel nonopioid analgesic.\\n\\n4. **I3 Receptors and Insulin Secretion**: While less understood, I3 receptors are suggested to interact with ATP-sensitive potassium channels in pancreatic beta cells, possibly affecting insulin secretion.\\n\\nOverall, the research presented in this article highlights the potential of targeting imidazoline receptors for the treatment of various conditions, which could contribute to improved health and potentially extended lifespans. It also underscores the ongoing need for further research to fully understand the mechanisms and therapeutic potentials of these receptors.<|im_end|>\""}
----------------------------------------
{"answer":"\"<|im_start|> system\\n        Describe this for a person interested in life extension who is well educated about life extension methods.<|im_end|> \\n        <|im_start|> user\\n        1. Arch Biochem Biophys. 2021 Apr 15;701:108817. doi: 10.1016/j.abb.2021.108817. \\nEpub 2021 Feb 21.\\n\\nProtein kinase C-mediated calcium signaling as the basis for cardiomyocyte \\nplasticity.\\n\\nMaltsev AV(1), Evdokimovskii EV(2), Kokoz YM(2).\\n\\nAuthor information:\\n(1)Institute of Theoretical and Experimental Biophysics, Russian Academy of \\nSciences, Moscow Region, Pushchino, Institutskaya, 3, 142290, Russia; Institute \\nof Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, \\nMoscow, Butlerova 5А, 117485, Russia. Electronic address: \\nalex.v.maltsev88@gmail.com.\\n(2)Institute of Theoretical and Experimental Biophysics, Russian Academy of \\nSciences, Moscow Region, Pushchino, Institutskaya, 3, 142290, Russia.\\n\\nProtein kinase C is the superfamily of intracellular effector molecules which \\ncontrol crucial cellular functions. Here, we for the first time did the \\npercentage estimation of all known PKC and PKC-related isozymes at the \\nindividual cadiomyocyte level. Broad spectrum of PKC transcripts is expressed in \\nthe left ventricular myocytes. In addition to the well-known 'heart-specific' \\nPKCα, cardiomyocytes have the high expression levels of PKCN1, PKCδ, PKCD2, \\nPKCε. In general, we detected all PKC isoforms excluding PKCη. In cardiomyocytes \\nPKC activity tonically regulates voltage-gated Ca2+-currents, intracellular Ca2+ \\nlevel and nitric oxide (NO) production. Imidazoline receptor of the first type \\n(I1R)-mediated induction of the PKC activity positively modulates Ca2+ release \\nthrough ryanodine receptor (RyR), increasing the Ca2+ leakage in the cytosol. In \\ncardiomyocytes with the Ca2+-overloaded regions of > 9-10 μm size, the local \\nPKC-induced Ca2+ signaling is transformed to global accompanied by spontaneous \\nCa2+ waves propagation across the entire cell perimeter. Such switching of Ca2+ \\nsignaling in cardiac cells can be important for the development of several \\ncardiovascular pathologies and/or myocardial plasticity at the cardiomyocyte \\nlevel.\\n\\nCopyright © 2021 Elsevier Inc. All rights reserved.\\n\\nDOI: 10.1016/j.abb.2021.108817\\nPMID: 33626379 [Indexed for MEDLINE]\\n<|im_end|> \\n        <|im_start|> assistant\\n        This article discusses the role of protein kinase C (PKC) in mediating calcium signaling within cardiomyocytes, which are the muscle cells of the heart. PKC is a family of enzymes that play a critical role in regulating various cellular processes. The study found that multiple PKC isoforms are present in left ventricular myocytes, including PKCα, PKCN1, PKCδ, PKCD2, and PKCε, but not PKCη.\\n\\nThe researchers also found that PKC activity influences voltage-gated calcium currents, intracellular calcium levels, and nitric oxide (NO) production in cardiomyocytes. When activated by imidazoline receptor of the first type (I1R), PKC increases calcium release through ryanodine receptors (RyRs), leading to elevated calcium concentrations within the cell.\\n\\nUnder certain conditions, localized PKC-induced calcium signaling can become global, spreading across the entire cell membrane. This transition may be linked to the development of cardiovascular diseases and could also be involved in the ability of cardiac cells to change their structure or function in response to injury or stress, a process known as myocardial plasticity.\\n\\nIn summary, the study sheds light on how PKC-mediated calcium signaling works at the molecular level within cardiomyocytes, providing insights into both normal physiological functioning and potential mechanisms underlying cardiovascular disorders.<|im_end|>\""}
----------------------------------------
{"answer":"\"<|im_start|> system\\n        Describe this for a person interested in life extension who is well educated about life extension methods.<|im_end|> \\n        <|im_start|> user\\n        1. Physiol Res. 2022 Dec 16;71(6):763-770. doi: 10.33549/physiolres.935041. Epub \\n2022 Nov 25.\\n\\nBlood pressure reduction induced by chronic intracerebroventricular or peroral \\nclonidine administration in rats with salt-dependent or angiotensin II-dependent \\nhypertension.\\n\\nZicha J(1), Řezáčová L, Behuliak M, Vaněčková I.\\n\\nAuthor information:\\n(1)Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. \\nJosef.Zicha@fgu.cas.cz.\\n\\nThe agonists of alpha(2)-adrenergic receptors such as clonidine, rilmenidine or \\nmonoxidine are known to lower blood pressure (BP) through a reduction of brain \\nsympathetic outflow but their chronic antihypertensive effects in rats with \\nlow-renin or high-renin forms of experimental hypertension were not studied yet. \\nMoreover, there is no comparison of mechanisms underlying BP reduction elicited \\nby chronic peroral (po) or intracerebroventricular (icv) clonidine treatment. \\nMale salt-sensitive Dahl rats fed 4% NaCl diet and Ren-2 transgenic rats were \\ntreated with clonidine administered either in the drinking fluid (0.5 mg/kg/day \\npo) or as the infusion into lateral brain ventricle (0.1 mg/kg/day icv) for 4 \\nweeks. Basal BP and the contributions of renin-angiotensin system (captopril 10 \\nmg/kg iv) or sympathetic nervous system (pentolinium 5 mg/kg iv) to BP \\nmaintenance were determined in conscious cannulated rats at the end of the \\nstudy. Both peroral and intracerebroventricular clonidine treatment lowered BP \\nto the same extent in either rat model. However, in both models chronic \\nclonidine treatment reduced sympathetic BP component only in rats treated \\nintracerebroventricularly but not in perorally treated animals. In contrast, \\nperoral clonidine treatment reduced angiotensin II-dependent vasoconstriction in \\nRen-2 transgenic rats, whereas it lowered residual blood pressure in Dahl rats. \\nIn conclusions, our results indicate different mechanisms of antihypertensive \\naction of clonidine when administered centrally or systemically.\\n\\nDOI: 10.33549/physiolres.935041\\nPMCID: PMC9814981\\nPMID: 36426892 [Indexed for MEDLINE]\\n\\nConflict of interest statement: Conflict of Interest There is no conflict of \\ninterest.\\n<|im_end|> \\n        <|im_start|> assistant\\n        For individuals interested in life extension, understanding how various treatments can impact blood pressure is crucial, as hypertension is a significant risk factor for cardiovascular disease, which is one of the leading causes of death worldwide. The study you've shared provides insights into the potential benefits of clonidine, an α2-adrenergic receptor agonist, in reducing blood pressure in rats with different types of hypertension.\\n\\nHere's a summary of the key points from the study:\\n\\n1. **Chronic Clonidine Treatment Lowers Blood Pressure**: Whether administered orally or directly into the brain via intracerebroventricular injection, clonidine effectively reduces blood pressure in rats with both low-renin and high-renin forms of hypertension.\\n\\n2. **Central versus Peripheral Administration**: While the decrease in blood pressure is comparable with both methods, the mechanisms behind the reduction differ. Central administration appears to work primarily by reducing sympathetic outflow from the brain, while systemic (peroral) administration may act on other mechanisms, such as inhibiting the renin-angiotensin system or affecting angiotensin II-dependent vasoconstriction.\\n\\n3. **Sympathetic Nervous System Involvement**: Only rats receiving intracerebroventricular clonidine showed a reduction in the sympathetic component of blood pressure maintenance, suggesting that central pathways are more sensitive to clonidine's effects on sympathetic tone.\\n\\n4. **Angiotensin II-Dependent Hypertension**: Peroral clonidine treatment was effective in lowering angiotensin II-dependent vasoconstriction in Ren-2 transgenic rats, indicating a specific effect on this pathway.\\n\\nThese findings suggest that clonidine could be a useful therapeutic agent for managing hypertension, potentially offering both central and peripheral modes of action depending on the route of administration. For those considering life extension strategies, this study highlights the importance of understanding the complexities of blood pressure regulation and the potential of targeted interventions to maintain cardiovascular health over the lifespan.<|im_end|>\""}
----------------------------------------
{"answer":"\"<|im_start|> system\\n        Describe this for a person interested in life extension who is well educated about life extension methods.<|im_end|> \\n        <|im_start|> user\\n        1. Neurobiol Dis. 2021 Jul;154:105359. doi: 10.1016/j.nbd.2021.105359. Epub 2021 \\nMar 30.\\n\\nStimulation of mTOR-independent autophagy and mitophagy by rilmenidine \\nexacerbates the phenotype of transgenic TDP-43 mice.\\n\\nPerera ND(1), Tomas D(1), Wanniarachchillage N(1), Cuic B(1), Luikinga SJ(1), \\nRytova V(1), Turner BJ(2).\\n\\nAuthor information:\\n(1)Florey Institute of Neuroscience and Mental Health, University of Melbourne, \\nParkville, Victoria 3052, Australia.\\n(2)Florey Institute of Neuroscience and Mental Health, University of Melbourne, \\nParkville, Victoria 3052, Australia; Perron Institute for Neurological and \\nTranslational Science, Queen Elizabeth Medical Centre, Nedlands, Western \\nAustralia 6150, Australia. Electronic address: bradley.turner@florey.edu.au.\\n\\nAutophagy, which mediates the delivery of cytoplasmic substrates to the lysosome \\nfor degradation, is essential for maintaining proper cell homeostasis in \\nphysiology, ageing, and disease. There is increasing evidence that autophagy is \\ndefective in neurodegenerative disorders, including motor neurons affected in \\namyotrophic lateral sclerosis (ALS). Restoring impaired autophagy in motor \\nneurons may therefore represent a rational approach for ALS. Here, we \\ndemonstrate autophagy impairment in spinal cords of mice expressing mutant \\nTDP-43Q331K or co-expressing TDP-43WTxQ331K transgenes. The clinically approved \\nanti-hypertensive drug rilmenidine was used to stimulate mTOR-independent \\nautophagy in double transgenic TDP-43WTxQ331K mice to alleviate impaired \\nautophagy. Although rilmenidine treatment induced robust autophagy in spinal \\ncords, this exacerbated the phenotype of TDP-43WTxQ331K mice, shown by truncated \\nlifespan, accelerated motor neuron loss, and pronounced nuclear TDP-43 \\nclearance. Importantly, rilmenidine significantly promoted mitophagy in spinal \\ncords TDP-43WTxQ331K mice, evidenced by reduced mitochondrial markers and load \\nin spinal motor neurons. These results suggest that autophagy induction \\naccelerates the phenotype of this TDP-43 mouse model of ALS, most likely through \\nexcessive mitochondrial clearance in motor neurons. These findings also \\nemphasise the importance of balancing autophagy stimulation with the potential \\nnegative consequences of hyperactive mitophagy in ALS and other \\nneurodegenerative diseases.\\n\\nCopyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.\\n\\nDOI: 10.1016/j.nbd.2021.105359\\nPMID: 33798740 [Indexed for MEDLINE]\\n<|im_end|> \\n        <|im_start|> assistant\\n        For someone interested in life extension who has a good understanding of life extension methods, this article would be relevant because it discusses a potential therapeutic intervention that targets autophagy, a cellular process involved in the degradation of proteins and organelles, which is crucial for maintaining cellular health and preventing the accumulation of damaged molecules that can lead to disease.\\n\\nThe study investigates the use of rilmenidine, an anti-hypertensive drug, as a means to stimulate autophagy independently of the mTOR pathway, which is known to regulate cell growth and longevity. The researchers found that while rilmenidine effectively induces autophagy in a mouse model of ALS (amyotrophic lateral sclerosis), it unexpectedly accelerates the disease's progression and shortens the lifespan of the mice. This counterintuitive result suggests that there may be complexities in manipulating autophagy for therapeutic purposes and that more research is needed to fully understand how to modulate this process effectively.\\n\\nThe article also highlights the role of mitophagy, which is the specific autophagy of mitochondria, in neuronal health. While rilmenidine promotes mitophagy, leading to decreased mitochondrial load in motor neurons, this does not translate into a beneficial effect on the mice's health. Instead, it appears to exacerbate the neurological symptoms and mortality rate.\\n\\nOverall, this study provides valuable insights into the challenges of targeting autophagy for treating neurodegenerative diseases and potentially other conditions related to aging. It emphasizes the need for caution when developing therapies that aim to manipulate fundamental biological processes like autophagy and suggests that a nuanced understanding of these processes is necessary to avoid unintended consequences. For enthusiasts of life extension, this article would serve as a reminder that the path to extending human healthspan is fraught with scientific complexity and that safe and effective interventions will require careful study and consideration of the intricate balance between different cellular mechanisms.<|im_end|>\""}
----------------------------------------
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>502</title>
    <link rel="preconnect" href="https://fonts.googleapis.com" />
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
    <link
            href="https://fonts.googleapis.com/css2?family=Inter:wght@500;700&display=swap"
            rel="stylesheet"
    />
    <style>
        * {
            margin: 0;
            padding: 0;
        }

        html {
            font-size: 16px;
        }

        body {
            background: #232a55;
            color: #e2e7f0;
            font-family: "Inter", sans-serif;
            line-height: 1.4;
            font-weight: 500;
            -webkit-font-smoothing: antialiased;
            -moz-osx-font-smoothing: grayscale;
            display: flex;
            flex-direction: column;
            min-height: 100vh;
        }

        main {
            flex: 1;
            width: 100%;
            max-width: 880px;
            margin: 4rem auto;
        }

        .wrapper {
            display: flex;
            padding: 0 2rem;
        }

        h1 {
            font-size: 2.25rem;
            font-weight: 700;
        }

        p {
            font-weight: 600;
            font-size: 1.3rem;
        }

        .svg-502 {
            margin-right: 2.5rem;
        }

        ul {
            list-style: none;
            padding-left: 2rem;
        }

        li {
            position: relative;
            padding-left: 2rem;
            font-size: 1.25rem;
        }

        li:before {
            content: "";
            position: absolute;
            width: 1rem;
            height: 1rem;
            top: 0;
            left: 0;
            bottom: 0;
            margin: auto;
            border-radius: 0.8px 0.8px 0.8px 4.7px;
            transform: matrix(-0.91, -0.41, -0.41, 0.91, 0, 0);
        }

        .red-radish:before {
            background: #ff5c88;
        }

        .aurora-light:before {
            background: #8afadc;
        }

        .gold:before {
            background: #ffda5d;
        }

        a {
            color: inherit;
            text-decoration: none;
        }

        h1 {
            display: inline-block;
            margin-right: 1rem;
        }

        p {
            margin-bottom: 2rem;
        }

        ul {
            margin-bottom: 3.5rem;
        }

        li {
            margin-bottom: 2.5rem;
        }

        ul:last-of-type li:last-of-type {
            margin-bottom: 5rem;
        }

        header {
            margin-top: 0.75rem;
            margin-bottom: 1.5rem;
        }

        .tag {
            display: inline-block;
            padding: 6px 8px;
            font-family: inherit;
            font-weight: inherit;
            font-size: 1rem;
            font-weight: 700;
            line-height: 1.2;
            border: 1.5px solid #98a2b8;
            border-radius: 4px;
            color: #98a2b8;
            white-space: nowrap;
            vertical-align: text-bottom;
        }

        a {
            text-transform: uppercase;
            font-size: 0.9375rem;
            font-family: inherit;
            letter-spacing: 0.4px;
            white-space: nowrap;
            color: #fff;
        }

        .link-primary, .link-tertiary {
            display: inline-block;
            margin-right: 1rem;
            margin-bottom: 1rem;
        }

       .link-tertiary {
            border-bottom: 1px solid #fff;
        }

        .link-primary {
            padding: 11px 20px;
            background: #4f65f1;
            border-radius: 48px;
        }

        .link-primary:hover {
            background: #4448ec;
        }

        .text-502,
        .text-or {
            display: none;
        }

        .powered-by {
          display: flex;
          align-items: center;
          justify-content: center;
          width: 100%;
          background: #181B38;
          padding: 2.5rem 0;
        }

        .logo {
          display: flex;
          align-items: baseline;
          font-size: 0.75rem;
          color: #fff;
        }

        .logo span {
          margin-right: 0.5rem;
        }

        @media screen and (max-width: 720px) {
            ul {
                padding-left: 0;
            }

            h1 {
                display: block;
            }

            p {
                margin-bottom: 1.5rem;
            }

            li {
                margin-bottom: 2rem;
            }

            .link-primary, .link-tertiary {
                margin-right: 0;
            }

            .tag {
                margin: 1rem auto 2rem;
            }

            .svg-502 {
                display: none;
            }

            .text-502 {
                display: inline;
            }

            footer {
                display: flex;
                flex-direction: column;
                align-items: center;
            }

            .text-or {
                display: block;
                margin: 1.5rem auto;
                text-transform: uppercase;
            }
        }
    </style>
</head>
<body>
<main>
    <div class="wrapper">
        <div>
            <svg    class="svg-502"
                    width="170"
                    height="600"
                    viewBox="0 0 170 600"
                    fill="none"
                    xmlns="http://www.w3.org/2000/svg"
            >
                <title>502</title>
                <path
                        d="M150.708 149.832V147.928C150.708 106.516 120.958 94.854 79.784 94.854H72.882L75.738 62.01H140.474C143.092 62.01 145.234 60.106 145.234 57.488V33.688C145.234 31.07 143.092 29.166 140.474 29.166H47.892C45.512 29.166 43.37 31.308 43.132 33.688L35.754 122.462V122.7C35.754 124.366 37.182 126.032 39.086 126.032H75.976C102.394 126.032 109.772 131.982 109.772 147.928V149.832C109.772 166.254 105.012 175.774 82.402 175.774C73.596 175.774 54.556 174.584 39.562 172.918C39.324 172.918 39.086 172.918 39.086 172.918C36.706 172.918 34.802 174.584 34.802 177.202V196.004C34.802 199.336 37.182 200.526 39.562 201.24C53.366 205.524 71.216 208.142 86.448 208.142C128.098 208.142 150.708 187.436 150.708 149.832Z"
                        fill="#181B38"
                />
                <path
                        d="M156.896 324.936V304.468C156.896 247.348 133.096 224.024 92.636 224.024C52.176 224.024 28.614 247.348 28.614 304.468V324.936C28.614 382.056 52.176 405.142 92.636 405.142C133.096 405.142 156.896 382.056 156.896 324.936ZM116.198 324.936C116.198 362.54 105.964 371.346 92.636 371.346C79.308 371.346 69.312 362.54 69.312 324.936V304.468C69.312 266.864 79.308 257.82 92.636 257.82C105.964 257.82 116.198 266.864 116.198 304.468V324.936Z"
                        fill="#181B38"
                />
                <path
                        d="M151.66 466.482C151.66 436.018 134.762 421.024 90.97 421.024C73.358 421.024 53.604 424.356 40.276 428.402C37.896 429.116 35.754 430.544 35.754 432.924V451.488C35.754 454.106 37.42 456.248 40.038 456.248C40.276 456.248 40.276 456.248 40.514 456.248C55.032 454.82 72.882 453.154 87.4 453.154C106.678 453.154 112.628 457.2 112.628 467.434C112.628 478.62 109.058 480.524 88.352 495.042L66.456 510.512C48.368 523.364 34.088 544.784 34.088 570.964V595.24C34.088 597.858 36.23 600 38.848 600H144.758C147.376 600 149.518 597.858 149.518 595.24V570.726C149.518 568.108 147.376 566.204 144.758 566.204H69.55V565.252C69.55 548.592 83.83 538.358 104.06 524.792L124.29 511.226C141.902 499.326 151.66 485.76 151.66 466.482Z"
                        fill="#181B38"
                />
                <path
                        d="M134.708 140.832V138.928C134.708 97.516 104.958 85.854 63.784 85.854H56.882L59.738 53.01H124.474C127.092 53.01 129.234 51.106 129.234 48.488V24.688C129.234 22.07 127.092 20.166 124.474 20.166H31.892C29.512 20.166 27.37 22.308 27.132 24.688L19.754 113.462V113.7C19.754 115.366 21.182 117.032 23.086 117.032H59.976C86.394 117.032 93.772 122.982 93.772 138.928V140.832C93.772 157.254 89.012 166.774 66.402 166.774C57.596 166.774 38.556 165.584 23.562 163.918C23.324 163.918 23.086 163.918 23.086 163.918C20.706 163.918 18.802 165.584 18.802 168.202V187.004C18.802 190.336 21.182 191.526 23.562 192.24C37.366 196.524 55.216 199.142 70.448 199.142C112.098 199.142 134.708 178.436 134.708 140.832Z"
                        fill="#E2E7F0"
                />
                <path
                        d="M140.896 315.936V295.468C140.896 238.348 117.096 215.024 76.636 215.024C36.176 215.024 12.614 238.348 12.614 295.468V315.936C12.614 373.056 36.176 396.142 76.636 396.142C117.096 396.142 140.896 373.056 140.896 315.936ZM100.198 315.936C100.198 353.54 89.964 362.346 76.636 362.346C63.308 362.346 53.312 353.54 53.312 315.936V295.468C53.312 257.864 63.308 248.82 76.636 248.82C89.964 248.82 100.198 257.864 100.198 295.468V315.936Z"
                        fill="#E2E7F0"
                />
                <path
                        d="M135.66 457.482C135.66 427.018 118.762 412.024 74.97 412.024C57.358 412.024 37.604 415.356 24.276 419.402C21.896 420.116 19.754 421.544 19.754 423.924V442.488C19.754 445.106 21.42 447.248 24.038 447.248C24.276 447.248 24.276 447.248 24.514 447.248C39.032 445.82 56.882 444.154 71.4 444.154C90.678 444.154 96.628 448.2 96.628 458.434C96.628 469.62 93.058 471.524 72.352 486.042L50.456 501.512C32.368 514.364 18.088 535.784 18.088 561.964V586.24C18.088 588.858 20.23 591 22.848 591H128.758C131.376 591 133.518 588.858 133.518 586.24V561.726C133.518 559.108 131.376 557.204 128.758 557.204H53.55V556.252C53.55 539.592 67.83 529.358 88.06 515.792L108.29 502.226C125.902 490.326 135.66 476.76 135.66 457.482Z"
                        fill="#E2E7F0"
                />
            </svg>
        </div>
        <div>
            <header>
                <h1><span class="text-502">502 </span>Bad Gateway</h1>
                <span class="tag">Request ID: 82eae76eb3a62d5a-YVR</span>
            </header>
            <p>If you are a visitor:</p>
            <ul>
                <li class="red-radish">Try again later or contact the site owner.</li>
            </ul>
            <p>If you are the site owner, your application was unable to serve this request. Common reasons include:</p>
            <ul>
                <li class="aurora-light">
                    You recently created a service and it has not yet completed a
                    successful deploy.
                </li>
                <li class="gold">
                    Your application has crashed or failed its health check.
                </li>
            </ul>
            <footer>
                <a href="https://dashboard.render.com/" class="link-primary">
                    Check Dashboard
                </a>
                <span class="text-or">or</span>
                <a href="https://status.render.com/" class="link-tertiary"> View System Status </a>
            </footer>
        </div>
    </div>
</main>
<div class="powered-by">
  <div class="logo">
    <span>Powered by</span>
    <a href="https://render.com/">
      <svg width="75" height="24" viewBox="0 0 75 24" fill="none" xmlns="http://www.w3.org/2000/svg">
        <title>Render</title>
        <g clip-path="url(#clip0_70_62)">
        <path d="M7.21155 9.97638C7.21155 9.87119 7.1692 9.7703 7.09382 9.69593C7.01844 9.62155 6.9162 9.57976 6.8096 9.57976C5.51151 9.56992 4.24737 9.98875 3.21833 10.7696L3.03877 10.9045V10.1549C3.03877 10.0494 2.99628 9.94814 2.92064 9.87351C2.845 9.79887 2.74241 9.75694 2.63544 9.75694H0.401951C0.295222 9.7573 0.192989 9.79939 0.117649 9.87399C0.0423086 9.94858 4.96047e-06 10.0496 5.58636e-06 10.1549V23.3754C-0.000552896 23.4834 0.0407821 23.5874 0.115527 23.6663C0.190273 23.7451 0.292758 23.7927 0.401951 23.7993H2.76252C2.87208 23.7934 2.9751 23.746 3.05021 23.6671C3.12531 23.5881 3.16672 23.4837 3.16585 23.3754V13.1452L3.22386 13.1152C4.47528 12.4678 5.54713 12.1925 6.81513 12.1925C6.9221 12.1925 7.02468 12.1506 7.10032 12.0759C7.17596 12.0013 7.21845 11.9001 7.21845 11.7945L7.21155 9.97638Z" fill="#E2E7F0"/>
        <path d="M20.4551 15.8927C20.4551 11.9988 18.1595 9.57959 14.4674 9.57959C10.6841 9.57959 8.42578 11.9388 8.42578 15.8927V17.7627C8.42578 23.6996 13.4991 24.0009 14.5171 24.0009C16.8653 24.0009 17.8722 23.8646 19.4675 23.5743C19.8571 23.5088 19.9151 23.3916 19.9151 23.0291V21.3527C19.9151 21.1019 19.6457 21.0801 19.5642 21.0801H19.4869C18.3404 21.1877 16.5862 21.3322 14.7727 21.3322C11.8983 21.3322 11.5958 19.0152 11.5958 18.0135V17.8295H20.0573C20.2452 17.8295 20.4607 17.7695 20.4607 17.3061L20.4551 15.8927ZM17.2658 15.6747H11.6151V15.4648C11.6151 13.5089 12.7339 12.2469 14.4674 12.2469C16.1677 12.2469 17.2658 13.5089 17.2658 15.4648V15.6747Z" fill="#E2E7F0"/>
        <path d="M34.9269 15.1287C34.9269 12.2433 34.4034 9.57471 30.605 9.57471C28.9254 9.57471 27.9695 9.84729 26.5123 10.7714L26.3438 10.8763V10.1526C26.3438 10.047 26.3013 9.94582 26.2257 9.87118C26.15 9.79654 26.0474 9.75461 25.9405 9.75461H23.7111C23.6044 9.75498 23.5022 9.79706 23.4268 9.87166C23.3515 9.94626 23.3092 10.0473 23.3092 10.1526V23.3731C23.3086 23.4811 23.35 23.5851 23.4247 23.6639C23.4994 23.7428 23.6019 23.7904 23.7111 23.797H26.0731C26.1825 23.7907 26.2853 23.7432 26.3604 23.6644C26.4354 23.5855 26.4769 23.4813 26.4764 23.3731V13.1442L26.5344 13.1143C27.7679 12.4764 28.6767 12.1915 29.4806 12.1915C31.5815 12.1915 31.7694 12.948 31.7694 15.1287V23.3704C31.7688 23.4785 31.8104 23.5828 31.8854 23.6617C31.9604 23.7405 32.0633 23.788 32.1727 23.7943H34.5319C34.6411 23.7876 34.7436 23.74 34.8183 23.6612C34.8931 23.5824 34.9344 23.4783 34.9338 23.3704L34.9269 15.1287Z" fill="#E2E7F0"/>
        <path d="M49.4493 22.7686V5.17988C49.4507 5.12682 49.4414 5.074 49.4219 5.02454C49.4024 4.97508 49.3731 4.92998 49.3356 4.89188C49.2981 4.85378 49.2533 4.82346 49.2038 4.8027C49.1543 4.78194 49.1011 4.77116 49.0473 4.771H46.6868C46.6332 4.77152 46.5803 4.78256 46.5311 4.80348C46.4819 4.8244 46.4374 4.85478 46.4003 4.89285C46.3631 4.93091 46.334 4.97589 46.3147 5.02517C46.2953 5.07446 46.2861 5.12705 46.2876 5.17988V9.77162L46.1633 9.75526C45.3531 9.6436 44.5364 9.58487 43.7184 9.57945C39.8399 9.57945 37.7086 11.7942 37.7086 15.8108V17.7571C37.7086 21.7805 39.844 23.9953 43.7226 23.9953C45.45 23.9788 47.1693 23.7596 48.8443 23.3424C49.4009 23.2034 49.4493 23.0807 49.4493 22.7686ZM46.2862 21.2898L46.1992 21.3075C45.3768 21.4345 44.5452 21.4942 43.7129 21.4861C41.1852 21.4861 40.862 19.4962 40.862 17.7625V15.8108C40.862 14.0771 41.1852 12.0873 43.7129 12.0873C44.5413 12.1001 45.3682 12.1602 46.1895 12.2672L46.2834 12.2808L46.2862 21.2898Z" fill="#E2E7F0"/>
        <path d="M64.3337 15.8927C64.3337 11.9988 62.0395 9.57959 58.3446 9.57959C54.5627 9.57959 52.3058 11.9388 52.3058 15.8927V17.7627C52.3058 23.6996 57.3791 24.0009 58.3971 24.0009C60.7452 24.0009 61.7508 23.8646 63.3461 23.5743C63.737 23.5088 63.7964 23.3916 63.7964 23.0291V21.3527C63.7964 21.1019 63.5202 21.0801 63.4442 21.0801H63.3669C62.2204 21.1877 60.4662 21.3322 58.6526 21.3322C55.7796 21.3322 55.4688 19.0152 55.4688 18.0135V17.8295H63.9304C64.1183 17.8295 64.3337 17.7695 64.3337 17.3061V15.8927ZM61.1444 15.6747H55.4937V15.4648C55.4937 13.5089 56.6139 12.2469 58.3446 12.2469C60.0463 12.2469 61.1444 13.5089 61.1444 15.4648V15.6747Z" fill="#E2E7F0"/>
        <path d="M74.3975 9.97641C74.3975 9.87122 74.3552 9.77034 74.2798 9.69596C74.2044 9.62158 74.1022 9.57979 73.9956 9.57979C72.6954 9.56909 71.429 9.9874 70.3974 10.7683L70.222 10.9046V10.155C70.2212 10.0494 70.1783 9.94837 70.1025 9.87385C70.0268 9.79933 69.9242 9.75733 69.8172 9.75697H67.5893C67.4823 9.75697 67.3797 9.7989 67.3041 9.87354C67.2285 9.94817 67.186 10.0494 67.186 10.155V23.3755C67.1851 23.4837 67.2265 23.5882 67.3016 23.6671C67.3767 23.746 67.4797 23.7934 67.5893 23.7993H69.9457C70.0554 23.7934 70.1586 23.7461 70.2339 23.6672C70.3092 23.5883 70.3509 23.4839 70.3504 23.3755V13.1452L70.407 13.1153C71.6585 12.4679 72.7303 12.1925 73.9983 12.1925C74.105 12.1922 74.2073 12.1501 74.2826 12.0755C74.358 12.0009 74.4003 11.8999 74.4003 11.7946L74.3975 9.97641Z" fill="#E2E7F0"/>
        </g>
        <defs>
        <clipPath id="clip0_70_62">
        <rect width="74.4" height="24" fill="white"/>
        </clipPath>
        </defs>
      </svg>
    </a>
  </div>
  </div>
</body>
</html>

----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
{"answer":"modal-http: Webhook failed: workspace billing cycle spend limit reached\n"}
----------------------------------------
